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ABSTRACT: The aim of this study was to investigate the solid dispersion phase behavior 
of S- o r RS-ibuprofen in stearic acid. By means of thermal analysis, we have demonstrated 
the total immiscibility, in solid state, of the corresponding binary mixtures. This indicates 
that no specific interactions exist between the chosen excipient and active pharmaceutical 
ingredient (API) that lead to eutectic systems. Furthermore, based on calorimetric and X-ray 
diffraction experiments, we have showed that upon cooling of the molten state, only stearic acid 
recrystallizes in the presence of S-ibuprofen, whereas a quaternary phase mixture is obtained 
for the racemic ibuprofen/stearic acid preparation. The solubility of stearic acid in S-ibuprofen 
liquid in all proportions was also determined. Overall, the results presented here offer an 
approach for the study of API/excipient interactions. 
Keywords: drug–excipient interactions; phase diagram; solid-state stability; miscibility; 
melt-recrystallization process; solubility; polymorphism; thermal analysis; X-ray powder 
diffraction
INTRODUCTION
Because 80% of active pharmaceutical ingredients
(APIs) are provided in the solid state, there are as
many conditioning steps in the industrial process as
there are solid APIs and excipients that vary regard-
ing their composition, density, granulometry, and/or
specific interaction. Lubricants are used in order to
prevent APIs from clumping together and from stick-
ing to tablet punches or capsule-filling machine, and
to ensure that tablet manufacturing and ejection can
occur with low friction between the solid and the die
wall. Commonminerals like talc or silica, magnesium
stearate, or stearic acid are the most frequently used
lubricants. During this process, a carrier is added to
an active ingredient to confer a given consistency, or
other physical characteristics, to the final product,
that is, the drug. However, any interaction with the
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active ingredient, particularly if it is a chemical one,
must be avoided. The lack of specific interactions in
the solid state between the active substance and the
excipient may be observed by studying the complete
phase diagram involving the two entities. This pa-
per presents results concerning the interaction be-
tween stearic acid and ibuprofen, which is a nons-
teroidal, anti-inflammatory API. The generic name
of this drug comes from a shortening of its chemi-
cal name, Iso-butyl-propanoic-phenolic acid. From
a chemical point of view, with one asymmetric car-
bon, ibuprofen has two enantiomers, namely the S-
and the R-ibuprofen (Figure 1a and 1b).
As is often the case with therapeutic compounds,
only one of the enantiomer is an active ingredient. For
ibuprofen, it has been proved that the S-enantiomer
is the active form.3–5 However, for economic reasons,
ibuprofen is commercialized in its racemic form. This
is due to the fact that the inactive R-(–)enantiomer
can easily be converted in vivo to the active form.6–8
Nevertheless, a certain quantity of R-enantiomer may
be retained in adipose tissues and cause unwanted ef-
fects. Therefore, a reduction in the dosage of ibuprofen
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Figure 1. Chemical structure of (a) S-ibuprofen and
(b) R-ibuprofen drawn from the corresponding X-ray crystal-
lographic information files.1,2 The asymmetric carbon atom
is represented by a gray motif.
could be obtained using pure S-ibuprofen as compared
with the racemic form.9
Association of ibuprofen and stearic acid is cur-
rently encountered in pharmaceutical manufacture
of tablets and topical gel. As far as tablets are con-
cerned, the API/excipient solid dispersion can be ho-
mogenized not only bymechanical powdermixing, but
also by cooling of a comelt of the two components. In
the latter case, when the components exhibit polymor-
phism, one cannot be sure that they crystallize into
themost stable crystalline phase. Because stearic acid
presents various polymorphic forms,10–17 the thermo-
dynamic stability of the ibuprofen/stearic acid solid
dispersion prepared from the melting–cooling process
must be ensured. However, a survey of the literature
points to a lack of information regarding the study
of the interactions between these components, in the
solid state, over the whole range of compositions.
This paper presents, on one hand, the study of
two binary phase diagrams between stearic acid and
S-ibuprofen or RS-ibuprofen, obtained from the solid
state. As a matter of fact, the phase behavior study
between S-ibuprofen and stearic acid has never been
reported up to now. On the other hand, stability of the
solid dispersions obtained from the molten state will
be investigated and discussed.
MATERIALS AND METHODS
S- and RS-ibuprofen (CAS number: 51146-56-6 and
15687-27-1, respectively; 99% purity) were purchased
from Acros Organics, part of Thermo Fisher Sci-
entific, Illkirch, France. Stearic acid (CAS number:
57-11-4; 98% purity) was obtained from Alfa Aesar,
Schiltigheim, France. The components were used as
received. For the binary mixture preparations, the
compounds were weighed separately and mechani-
cally mixed in a mortar in their solid state. Around 30
different compositions were prepared for each binary
system.
Thermal Analysis
Differential scanning calorimetry (DSC) runs were
performed at 2Kmin–1 from 25◦C to 90◦Cunder an at-
mosphere of dry nitrogen gas (flow rate: 60mLmin–1),
using a 822e calorimeter (Mettler-Toledo, Viroflay,
France), calibrated beforehand using high-purity in-
dium (99.99%, provided by Mettler-Toledo; temper-
ature and enthalpy of fusion: Tfus = 156.6◦C and
fus H = 28.45 J g–1, respectively). The DSC samples
were weighed in aluminum pans using a microbal-
ance sensitive to 1 :g and were hermetically sealed at
room temperature. The thermograms are represented
in this paper as the evolution of heat flow—arbitrary
unit—versus the scanned temperature in Celsius de-
grees. The temperature data were determined at the
onset of the thermograms single signal for the pure
compounds (Fig. 2a). For the binary mixtures, the eu-
tectic temperature was taken at the onset of the first
signal, that is, the beginning of the thermal transfor-
mation (Fig. 2b). The end of the thermal transforma-
tion (liquidus or solubility curve) was found out at the
extremum of the second signal (Fig. 2b).
X-ray Powder Diffraction
X-ray powder diffraction (XRPD) data were recorded
by means of a horizontally mounted Inel cylindrical,
position-sensitive detector (CPS-120; Inel, Artenay,
France) using Debye–Scherrer geometry (2θ from 1◦
to 106◦ with a 0.029 angular step) and equipped with
a liquid nitrogen 600 series Cryostream Cooler from
Oxford Cryosystems Ltd, Oxford, United Kingdom.
Monochromatic Cu K"1 (λ = 1.5406 Å) radiation pow-
ered with 1.0 kW (40 kV; 25 mA) was selected. Ex-
ternal calibration using Na2Ca3Al2F14 cubic phase
mixed with silver behenate was performed before-
hand by means of cubic spline fittings. Liquid sam-
ples were placed at room temperature into 0.5-mm di-
ameter Lindemann capillaries obtained from Bruker
AXS, Champs-sur-Marne, France. During data collec-
tion, the capillaries were rotated perpendicularly to
the X-ray beam direction to minimize possible effects
of preferred orientations.
Macroscopic Visualization of S-Ibuprofen/Stearic Acid
Mixtures
The components were weighted in a glass vial (total
amount of ∼180 mg). Each vial was first heated at
88◦C for 2 min in order to obtain a liquid phase. The
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Figure 2. DSC thermogram examples obtained for (a)
a pure compound and (b) a binary eutectic mixture. The
corresponding temperature assignments are indicated. En-
dothermic transformations give signals pointing up.
samples were then homogenized without opening the
vials and finally annealed at room temperature. Pic-
tures were taken 3 days after the melting process
using a two-megapixel CCD camera (Motic, Wetzlar,
Germany).
RESULTS AND DISCUSSION
The pure compounds were, first of all, analyzed by
thermal analysis and XRPD experiments. The XRPD
patterns are presented in Figure 3. The experimental
thermodynamic data obtained from the thermal anal-
ysis are in good agreement with the values reported
in the literature (Table 1). However, it is commonly
admitted that mixtures of stearic and palmitic acids
can be labeled as “stearic acid” in a certain range
of molar ratios between both components (USP32/
NF27 and Ph. Eur. 07/2010:1474). This implies that
Figure 3. XRPD patterns of (a) stearic acid, (b) RS-
ibuprofen, and (c) S-ibuprofen. For a same panel, the up-
per and lower curves correspond to the experimental and
calculated1,13,21 patterns, respectively.
depending on the batch, the stearic acid/palmitic acid
ratio may vary, leading to nonreproducible tempera-
ture and melting heat data.18,19 Furthermore, stearic
acid presents at least six polymorphic forms whose
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Table 1. Temperatures and Enthalpies of Fusion of Ibuprofen and the C-form of Stearic Acid
Stearic Acid References S-Ibuprofen References RS-Ibuprofen References
Tfus (◦C)
69.2 ± 0.7 This work 51.6 ± 0.2 This work 75.6 ± 0.3 This work
69.4 ± 0.1 22 45.8 23 70.8 23
69.6 24 52.2 25 75.2 ± 1.1 26
69.2 ± 0.3 20 53.6 27 75.4 25
75.6 27
75.8 28
fusH (kJ mol–1)
61.3 ± 1.3 This work 18.6 ± 0.3 This work 25.5 ± 0.3 This work
61.2 ± 0.2 22 19.9 ± 0.8 23 26.9 ± 1.0 23
61.3 24 18.7 ± 0.1 25 25.04 ± 0.10 26
63.2 ± 1.4 20 17.9 27 25.7 ± 0.2 25
25.5 27
25.8 ± 0.5 28
C-form is the high-temperature stable phase before
melting.20 As a matter of fact, no solid–solid phase
transition was observed for our batch of stearic acid.
This result indicates that the as-received product
crystallized in the C-form (monoclinic structure). It is
noteworthy that once the stearic acid is crystallized
from itsmolten phase into the C-form, nomore solid—
solid transition is obtained on heating or cooling.20
The study of the thermal behavior of ibuprofen
(Table 1) was also carried out. It is interesting to
emphasize that neither the S- nor the RS-compound
spontaneously recrystallizes upon cooling.
The RS-ibuprofen/stearic acid phase diagram
presents a eutectic equilibrium at 57.0 ± 0.3◦C
(Fig. 4). Besides, a complete demixing region in the
solid state is confirmed by the Tammann plot shown
in Figure 4 (dotted line). The enthalpy change at the
eutectic composition (xe) is estimated, from the Tam-
mann plot, to be 42.2 kJ mol–1 at xe = 0.553 mole
fraction in RS-ibuprofen.
The liquidus curves for the stearic acid follow a
quasi-ideal behavior. Taking into account an excess
Gibbs energy in the liquid state, approximately equal
to 0.2 kJ mol–1 at the eutectic point, and a complete
immiscibility in the solid state, the experimental liq-
uidus points were fitted (Fig. 4; solid blue lines) us-
ing an EXcess function coefficients from T-X phase
Diagram (EXTXD) analysis.29 Besides, no disconti-
nuity is observed in the Tammann plot, which inter-
cepts the eutectic enthalpy He = 0 at x = 0 and
x = 1 (Fig. 4b; dotted line), as well as in the liquidus
curves. Therefore, one can conclude that no stoichio-
metric compound is formed between stearic acid and
RS-ibuprofen contrary to Lerdkanchanaporn et al.’s
suggestion.19 Indeed, for mixtures between 0.42 and
0.65 molar ratios in ibuprofen, that is, around the
eutectic composition, they did not observe any DSC
signal corresponding to the liquidus curve. To explain
this point, they suggested the existence of a (stearic
acid)·(RS-ibuprofen)2 compound. In fact, as seen in
Figure 4, the DSC signals that correspond to the in-
variant and the liquidus overlap each other for com-
position near the eutectic point. The latter is due to
experimental limitation such as the scanning rate,
the sample weight, and so on. Thus, the liquidus be-
comes difficult to be apprehended. Moreover, the hy-
pothesis of the compound proposed by Lerdkanchana-
porn et al.19 is not supported by their own Tammann
plots.
As discussed above, mixtures containing stearic
and palmitic acids may be used as “stearic acid” label.
In this case, a pseudo-binary phase diagram from the
stearic acid/palmitic acid/RS-ibuprofen ternary phase
diagram should be considered, assuming that the
stearic acid/palmitic acid system presents miscibility
domains in the solid state near pure acid compositions
(formation of molecular AxB1–x alloys). This behavior
was previously encountered, for instance, for binary
systems between odd n-alkanes.30 The so-considered
alloys start to melt at lower temperatures than the
pure components ones, whatever the composition. We
noticed the same phenomenon regarding stearic acid
used by Gordon et al.18 to establish the phase dia-
gram with RS-ibuprofen. The depression of the melt-
ing point observed for stearic acid (59.0◦C instead of
69.2◦C) is certainly due to the impurity of the com-
pound, which results from an alloy between stearic
acid and, probably, palmitic acid. Consequently, the
pseudo-binary system formed between RS-ibuprofen
and this alloy necessarily leads to a eutectic equilib-
rium at a lower temperature than our proposed dia-
gram one.
The assumption of miscibility domains between
C16 and C18 acids is easily acceptable because they
present a structural similarity that may be quanti-
fied by using the degree of molecular isomorphism,
ε.31 ε = 1 − 

, where Δ is the non-overlapping vol-
ume and Γ the overlapping volume of the molecules.
For long-chain molecules, the latter expression can be
simplified, taking Δ equal to the difference in chain
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length and Γ equal to the number of carbon in the
shortest chain. In our case, the values of Δ and Γ are
2 and 16, respectively, leading to a degree ofmolecular
isomorphism of 0.875.
For the S-ibuprofen/stearic acid phase diagram, the
complete immiscibility in the solid state is also re-
vealed by the Tammann plot (Fig. 5). The eutectic
equilibrium was determined at 44.0 ± 0.3◦C with a
eutectic point at xe = 0.866; x corresponding to the
S-ibuprofen molar ratio. The enthalpy change at the
eutectic point was found to be equal to 26.14 kJ mol–1.
Besides, compared with the ideal behavior, a slight
deviation in the experimental liquidus curves can be
noticed. As for the first system, the best fit for the liq-
uidus points was obtained considering the liquid state
as nonideal. For that reason, an excess Gibbs energy
value of 200 Jmol–1 was introduced in the assessment
at the eutectic point.
Owing to the higher melting point of the racemate,
the shift of the eutectic point from pure ibuprofen is
more important for the racemate than for the enan-
tiomer. This shift is increased by the lower melting
entropy of S-ibuprofen (57 J mol–1 K–1) than that of
RS-ibuprofen (73 J mol–1 K–1).
Considering that solid dispersions can be prepared
from the molten state, the behavior of each system
namely S-ibuprofen/stearic acid and RS-ibuprofen/
stearic acid—was studied upon heating–cooling steps.
After cooling, for compositions between x = 0 (pure
stearic acid) and x = xe, molten mixtures of S-
ibuprofen and stearic acid did not undergo any eutec-
tic reaction upon heating (Fig. 6). The same tendency
has been previously reported with other systems.32
Our result indicates that below the eutectic temper-
ature, the equilibrium between solid stearic acid and
solid S-ibuprofenwas not established. Indeed the ther-
mograms obtained presented a unique endothermic
signal corresponding to the crossing of the liquidus
curve for pure stearic acid. From these results we
can conclude that only pure stearic acid recrystallizes
upon cooling of the S-ibuprofen/stearic acid mixtures.
As a consequence, a two-phase equilibrium between
pure solid stearic acid and a liquid composed of stearic
acid and S-ibuprofen was established. The exact com-
position of the liquid is then obtained by the solubility
curve of stearic acid in S-ibuprofen liquid. As a matter
of fact, the observed thermal event corresponds to the
solubility point of a more stable form of stearic acid,
the C-form.
For compositions comprised between x = xe and
x = 1, the same behavior on cooling was observed
(Fig. 6). Following the same statement upon heat-
ing, one could expect to cross the liquidus curve
for solid S-ibuprofen in this range of molar ratios.
Surprisingly, the endothermic one-signal observed
from each DSC thermogram still corresponded to the
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Figure 4. (a) Three-dimensional representation of se-
lected DSC thermograms obtained for the RS-ibuprofen/
stearic acid mixtures (red curves). Endothermic transfor-
mations give signals pointing up. (b) The corresponding T–x
phase diagram (left axis). The Tammann plot is represented
by the open circles and dotted lines (right axis). The eutec-
tic and liquidus curves are represented in cyan and blue,
respectively.
solubility curve of pure stearic acid in S-ibuprofen
liquid.
In other words, for the whole range of compositions,
when cooling molten mixtures of stearic acid and S-
ibuprofen, only stearic acid recrystallizes. The corol-
lary of this result is that upon heating the solubility
curve of stearic acid in S-ibuprofen is followed, what-
ever the molar ratio. Pictures of vials containing mix-
tures of S-ibuprofen and stearic acid at differentmolar
ratios, prepared in the sameway as the corresponding
DSC samples, confirm these statements (Fig. 7).
This result is in accordance with the fact that
pure S-ibuprofen does not spontaneously recrystallize
upon cooling.25 Besides, we proved that S-ibuprofen
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Figure 5. (a) 3D representation of selected DSC ther-
mograms obtained for the S-ibuprofen/stearic acid mix-
tures (red curves). Endothermic transformations give sig-
nals pointing up. (b) The corresponding T–x phase diagram
(left axis). The Tammann plot is represented by the open cir-
cles and dotted lines (right axis). The eutectic and liquidus
curves are represented in cyan and blue, respectively.
recrystallization never occurred even for samples an-
nealed at room temperature for 112 year (results not
shown). We demonstrate here that this behavior of S-
ibuprofen is not altered even in the presence of stearic
acid. The latter conjecture, proposed on the basis of
the thermal and visual experiments, was confirmed
by X-ray studies. Indeed, 3 days after being melted
at 80◦C and then annealed at room temperature,
the S-ibuprofen/stearic acid mixtures presented only
X-ray diffraction signals corresponding to pure stearic
acid.
The broad peak between 15◦ and 20◦ in 2θ is due
to the presence of an amorphous phase correspond-
ing to the liquid mixture in the sample. Moreover,
for binary samples with high S-ibuprofen concentra-
tion (x > 0.759), when comparing the experimental
X-ray diffraction patterns (Fig. 8) with the calculated
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Figure 6. (a) Three-dimensional representation of se-
lected DSC thermograms (red curves) obtained for the S-
ibuprofen/stearic acid mixtures and recorded upon heating
after cooling from the molten state. Endothermic transfor-
mations give signals pointing up. (b) The corresponding T–x
phase diagram. The liquidus curve is represented in blue.
ones (Fig. 9), especially around 2◦ and 22◦ in 2θ, we
observed that the stearic acid recrystallized into two
polymorphs, namely the C- and Em-forms. We propose
here that the presence of ibuprofen in the liquid state
may induce polymorphism during the stearic acid
recrystallization process. These structural data allow
explaining why the Em →C transition at around 45◦C
has not been observed with the thermal experiments
as might be expected (Fig. 6). Indeed, for S-ibuprofen
compositions lower than the eutectic composition, the
C-form of stearic acid is predominant as compared
with the Em-form, the latter being converted into C
with a small transition enthalpy (∼3 kJ mol–1). For
S-ibuprofen compositions higher than the eutectic
composition, the solubility temperatures are lower
than 45◦C. Accordingly, whatever the molar ratio, the
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Figure 7. Pictures of glass vials containing mixtures of S-ibuprofen and stearic acid. S-
ibuprofen molar ratios: 0.000, 0.501, 0.944, and 0.959, from left to right, respectively.
Figure 8. Experimental XRPD of (a) selected S-ibuprofen/stearic acid mixtures and (b) pure S-
ibuprofen. The patterns were shifted for clarity. (a) S-ibuprofen molar ratios: 0.000 (black), 0.334
(green), 0.501 (blue), and 0.929 (red). The samples were analyzed 3 days after being melted at
80◦C directly in the capillary, and then annealed at room temperature. (Insets) Corresponding
patterns focused between 1.2◦ and 2.8◦ (left) and between 20.8◦ and 22.8◦ (right). The ∗ indicates
the signal corresponding to the stearic acid Em-form.
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Figure 9. Calculated XRPD patterns of C- (black) and
Em-(red) stearic acid polymorphs; from Refs. 13 and 15, re-
spectively. The patterns were shifted for clarity.
solubility curve proposed in Figure 6 is not affected
by the so-considered solid–solid transition.
Interestingly, we found out that the S-ibuprofen/
stearic acid mixtures may totally recrystallize by ex-
ternal mechanical actions (homogenization or condi-
tioning). In this case, stearic acid polymorphism also
occurs during recrystallization (results not shown).
The nature and the proportions of the polymorphic
forms are random. As stearic acid presents at least
six polymorphs, it can be assumed that a S-ibuprofen/
stearic acid solid dispersion prepared from the homo-
geneous melt would lead to nonreproducible batches.
Consequently, different properties of the solid disper-
sions such as dissolution rate, bioavailability, and so
on could be expected. All these results taken together
provide a good justification for the S-ibuprofen/stearic
acid mixture preparation from the solid versus liquid
state from a pharmaceutical point of view. Besides,
it has to be noticed that the behavior of S-ibuprofen
mixtures with stearic acid should hold true for the
mixtures containing R-ibuprofen instead.
The RS-ibuprofen/stearic acid system was also
studied upon heating–cooling steps. Contrary to S-
ibuprofen, the racemic compound has a strong ten-
dency to recrystallize as can be predicted from the
Patterson ratio33 determined as 1.77 by Romero and
Rhodes.27 However, the recrystallization rate of the
racemic compound seems to be random and depends
on the degree of dissociation in the molten state.19,28
Dwivedi et al.23 showed that in the liquid state, RS-
ibuprofen is largely dissociated into its enantiomers.
Therefore, upon cooling, the nondissociated part of
RS-ibuprofen may recrystallize. As far as the enan-
tiomers resulting from the resolution are concerned,
our study shows that they do not recrystallize upon
cooling. As a consequence, the cooling step leads at
least to four components in arbitrary proportions. Ow-
ing to the nonreproducibility of the experimental re-
sults, the study of such a quaternary system proves
rather complicated.
CONCLUSION
We demonstrated that the use of stearic acid as an ex-
cipient is highly justified because the complete immis-
cibility between RS- or S-ibuprofen and stearic acid in
the solid state indicates that no specific interactions
exist between stearic acid and ibuprofen. In addition,
from the molten state, the recrystallization of the cor-
responding pharmaceutical mixtures is incomplete.
This is why the solid dispersion between ibuprofen
and stearic acid should be performed from the solid
state. Moreover, during stearic acid recrystallization,
polymorphic forms are formed and stabilized, which
leads to batch to batch nonreproducible phases. The
studies presented here allow a better understanding
of the API/excipient interactions for an adjusted for-
mulation approach.
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